Kingstone Capital Partners Texas LLC Makes New Investment in Eli Lilly and Company $LLY

Key Points

• Kingstone Capital Partners Texas LLC has acquired a new position in Eli Lilly and Company, purchasing 319,296 shares valued at approximately $247.54 million.
• Majority of Eli Lilly's stock (82.53%) is owned by institutional investors, with recent significant purchases from firms like Duquesne Family Office LLC, which increased its stake by 52.5%.
• Eli Lilly's most recent earnings report showed a 37.6% increase in revenue year-over-year, reporting $15.56 billion in revenue and $6.31 earnings per share, surpassing analyst estimates.

Kingstone Capital Partners Texas LLC bought a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 319,296 shares of the company's stock, valued at approximately $247,541,000.

Several other institutional investors have also recently added to or reduced their stakes in the stock. IFM Investors Pty Ltd increased its holdings in Eli Lilly and Company by 3.9% in the 2nd quarter. IFM Investors Pty Ltd now owns 158,272 shares of the company's stock valued at $123,378,000 after purchasing an additional 5,972 shares during the last quarter. Perkins Coie Trust Co increased its holdings in Eli Lilly and Company by 0.9% in the 2nd quarter. Perkins Coie Trust Co now owns 6,633 shares of the company's stock valued at $5,171,000 after purchasing an additional 62 shares during the last quarter. Oliver Lagore Vanvalin Investment Group acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at approximately $1,623,000. Legacy Financial Strategies LLC increased its holdings in Eli Lilly and Company by 9.8% in the 2nd quarter. Legacy Financial Strategies LLC now owns 799 shares of the company's stock valued at $623,000 after purchasing an additional 71 shares during the last quarter. Finally, Ryan Investment Management Inc. acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at approximately $709,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on LLY shares. Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Berenberg Bank restated a "hold" rating and issued a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday. JPMorgan Chase & Co. dropped their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a research note on Tuesday. Wall Street Zen downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus price target of $939.61.

Eli Lilly and Company Stock Performance

LLY stock traded down $9.41 during trading on Friday, hitting $753.52. The company had a trading volume of 7,319,147 shares, compared to its average volume of 3,181,974. The firm has a market cap of $713.18 billion, a PE ratio of 49.25, a price-to-earnings-growth ratio of 1.05 and a beta of 0.47. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $939.86. The firm has a 50-day moving average price of $738.37 and a 200-day moving average price of $770.79. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the previous year, the company earned $3.92 EPS. The firm's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend was Friday, August 15th. Eli Lilly and Company's payout ratio is currently 39.22%.

Insider Buying and Selling

In other news, EVP Daniel Skovronsky purchased 1,000 shares of the firm's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares of the company's stock, valued at $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director J Erik Fyrwald purchased 1,565 shares of the firm's stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 4,514 shares of company stock worth $2,894,841 in the last three months. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.